New COVID 'Cicada' Variant Is Spreading

Follow Drugslib on

By Physician’s Briefing Staff HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Judith Stewart, BPharm. Last updated on March 27, 2026.

via HealthDay

FRIDAY, March 27, 2026 — Another new COVID variant is starting to spread.

Health officials say the variant — known as BA.3.2 or "Cicada" — has been quietly circulating for years but is now being detected more often in the United States and around the world.

The U.S. Centers for Disease Control and Prevention (CDC) said in a March 19 report that cases are slowly increasing. The World Health Organization (WHO) has also added Cicada to its "variants under monitoring" list as it pops up in more countries, USA Today reported.

So far, BA.3.2 has been found in more than 20 countries. In some places, it makes up as much as 30 percent of cases.

“Monitoring the spread of BA.3.2 provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from a previous infection or vaccination,” the CDC wrote in its Morbidity and Mortality Weekly Report.

The variant was named after a breed of insects that rarely emerge into view because it stayed mostly "underground" once it was detected.

Dr. Robert Hopkins Jr., medical director of the National Foundation for Infectious Diseases, said the variant was first identified in a traveler coming to the United States in June 2025. The first U.S. case was reported in January.

Since then, Cicada has been found in wastewater samples from 132 locations across at least 25 states.

Globally, the first known case was in South Africa in November 2024. The uptick began in September 2025.

BA.3.2 stands out because it contains about 70 to 75 mutations, making it different from previous strains.

As of March 14, the variant made up about 3.7 percent of wastewater samples collected, according to tracking data. Another variant, XFG, remains most dominant at 53 percent, followed by LF.7 at 10.3 percent, USA Today said.

But the Cicada version has spread more widely in parts of Europe.

“It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain,” Hopkins told USA Today, adding that he is aware of concerns that it could drive a U.S. summer surge.

"Low vaccination rates and little to no public health effort toward stopping COVID infections and spread leaves us vulnerable," he said.

So far, symptoms appear to be similar to other COVID strains.

Those include:

  • Runny or stuffy nose
  • Headache
  • Fatigue
  • Sneezing
  • Sore throat
  • Coughing
  • Changes in taste or smell

    • Some people have also reported a very painful sore throat, sometimes called "razorblade throat."

    "I have not seen any data which indicates that Cicada is any more severe than other circulating variants," Hopkins said.

    In its report, the CDC said monitoring spread of the BA.3.2 variant provides "valuable information" about its potential to evade immunity provided by previous vaccination or infection.

    "The number of mutations from JN.1 viruses makes it less likely that the current vaccines will be highly effective against Cicada, but we need more data to better answer this question," Hopkins said.

    Nonetheless, vaccines should still help protect against severe illness and death.

    USA Today Article

    Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-03-28 01:51

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords